Atai Life Sciences and Beckley Psytech announced positive results from a Phase 2b clinical trial evaluating BPL-003, a treatment for treatment-resistant depression (TRD). The study achieved its ...
Atai Life Sciences (NASDAQ:ATAI) is one of the best-performing NASDAQ stocks according to analysts. On July 1, Atai Life Sciences and Beckley Psytech Limited jointly announced positive topline results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results